Prolonged corticosteroid therapy and lung abnormalities in patients after severe COVID-19 pneumonia.
Sarcoidosis vasculitis and diffuse lung diseases · 10.12.2024 · 41 (4) · e2024052-e2024052
DOI: 10.36141/svdld.v41i4.14331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 10.12.2024. Verfasst von Anja Ljilja Posavec und 9 weiteren Autor:innen. Beteiligte Einrichtung: Polyclinic for the Respiratory Tract Diseases. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Some of the hospitalized patients after severe COVID-19 pneumonia experience significant fall in peripheral saturation despite optimal treatment. Because of immune dysregulation in COVID-19 there are indications that prolonged corticosteroids could be considered in treating patients for persistent radiological sequelae and respiratory symptoms. OBJECTIVES: to investigate lung function and lung sequelae on high-resolution CT (HRCT) im COVID-19 patients who were treated with glucocorticoid therapy in two dose regimens with a control group of patients who did not receive additional glucocorticoid therapy. METHODS: In this prospective cohort research we studied patients who suffered from prolonged respiratory insufficiency after severe COVID-19 pneumonia. Patients received corticosteroid therapy in two dose regimens: for 14 days and for 3 months after discharge from the hospital. Control group of patients did not receive additional corticosteroid therapy. Lung function, post-COVID-19 symptoms, and lung abnormalities on CT scans were analyzed in three months follow-up and compared with the control group of patients. RESULTS: Patients who received prolonged corticosteroid therapy for three months did not have better CT findings of lung abnormalities, lung function, or symptoms recovery in comparison to the patients with 14 days of therapy and control group of patients. Onwards, control group had significantly fewer dyspnea symptoms (Chi-square test, p=0,04) and higher DLCO (Kruskal Wallis test, p=0,03). CONCLUSIONS: Supplementary corticosteroid therapy for patients after severe pneumonia and prolonged respiratory insufficiency with lung abnormalities after COVID-19 did not improve lung function or lung lesions on CT.
Schlagwörter
Autor:innen und Institutionen
- Polyclinic for the Respiratory Tract Diseases.
- Clinical Department of Diagnostic and Interventional Radiology, University Hospital Dubrava.
- Department of Nephrology, University Hospital Dubrava.
- Department of Pulmonology, University Hospital Dubrava.
- Department of Nuclear Medicine, University Hospital Dubrava.
- Special Hospital Radiochirurgia Zagreb.
Zitieren
APA
Ljilja Posavec, A., Cvetković Kučić, D., Zagorec, N., Malnar, L., Lalić, K., Zelenika, M., Kovačevič, I., Kušter, D., Mutvar, A., & Piskač Živković, N. (2024). Prolonged corticosteroid therapy and lung abnormalities in patients after severe COVID-19 pneumonia. Sarcoidosis vasculitis and diffuse lung diseases, 41(4), e2024052-e2024052. https://doi.org/10.36141/svdld.v41i4.14331
Vancouver
Ljilja Posavec A, Cvetković Kučić D, Zagorec N, Malnar L, Lalić K, Zelenika M, et al. Prolonged corticosteroid therapy and lung abnormalities in patients after severe COVID-19 pneumonia. Sarcoidosis vasculitis and diffuse lung diseases. 2024;41(4):e2024052-e2024052. doi:10.36141/svdld.v41i4.14331
BibTeX
@article{LjiljaPosavec2024,
author = {Ljilja Posavec, Anja and Cvetković Kučić, Daria and Zagorec, Nikola and Malnar, Linda and Lalić, Kristina and Zelenika, Marina and Kovačevič, Ivona and Kušter, Dinka and Mutvar, Andreja and Piskač Živković, Nevenka},
title = {Prolonged corticosteroid therapy and lung abnormalities in patients after severe COVID-19 pneumonia},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2024},
volume = {41},
number = {4},
pages = {e2024052--e2024052},
doi = {10.36141/svdld.v41i4.14331}
}
EUVIMED